BACKGROUND: As EPO treatment of chronic anemia of advanced renal disease is now the standard of care we examined if such treatment may slow the progression of renal function decline. METHODS: Data of 18 pre-ESRD patients were analyzed retrospectively 12 months prior and prospectively 12 months after the initiation of EPO. Mean creatinine was 5.0 +/- 1.8 mg/dL (Mean +/- SEM) when starting EPO at a weekly dose of 5000 +/- 500 units once the hematocrit was below 30 %. EPO dose was titrated monthly for a hematocrit between 33.0% and 37.0%. Metabolic complications and hypertension were controlled. RESULTS: At month_0 the average blood pressure was 148/76 +/- 5/4 mmHg and at month_12 it was 145/73 +/- 6/3 mmHg (p = 0.75 by 2 tailed paired Student's t test). 12/18 patients were on an ACE-i or ARB before month_0 and 14/18 were on it after (p = 0.71 by Fisher's 2 tailed exact test). The average hematocrit rose from 26.9% +/- 0.6 to 33.1 % +/- 0.1. When linear regression analysis was applied to pre- and post-EPO 1/creatinine data the mean rate of decline was -0.0140 +/- 0.0119 (mean +/- SD) and -0.0017 +/- 0.0090 (non-parametric Wilcoxon matched pairs signed rank sum test: Z value: -2.91; P = 0.004) respectively. 5/18 patients did not require dialysis 12 months after starting EPO (month_0). CONCLUSION: Treatment of the anemia of chronic renal failure with erythropoietin, when instituted together with vigorous metabolic control may slow the rate of renal function decline.
BACKGROUND: As EPO treatment of chronic anemia of advanced renal disease is now the standard of care we examined if such treatment may slow the progression of renal function decline. METHODS: Data of 18 pre-ESRDpatients were analyzed retrospectively 12 months prior and prospectively 12 months after the initiation of EPO. Mean creatinine was 5.0 +/- 1.8 mg/dL (Mean +/- SEM) when starting EPO at a weekly dose of 5000 +/- 500 units once the hematocrit was below 30 %. EPO dose was titrated monthly for a hematocrit between 33.0% and 37.0%. Metabolic complications and hypertension were controlled. RESULTS: At month_0 the average blood pressure was 148/76 +/- 5/4 mmHg and at month_12 it was 145/73 +/- 6/3 mmHg (p = 0.75 by 2 tailed paired Student's t test). 12/18 patients were on an ACE-i or ARB before month_0 and 14/18 were on it after (p = 0.71 by Fisher's 2 tailed exact test). The average hematocrit rose from 26.9% +/- 0.6 to 33.1 % +/- 0.1. When linear regression analysis was applied to pre- and post-EPO 1/creatinine data the mean rate of decline was -0.0140 +/- 0.0119 (mean +/- SD) and -0.0017 +/- 0.0090 (non-parametric Wilcoxon matched pairs signed rank sum test: Z value: -2.91; P = 0.004) respectively. 5/18 patients did not require dialysis 12 months after starting EPO (month_0). CONCLUSION: Treatment of the anemia of chronic renal failure with erythropoietin, when instituted together with vigorous metabolic control may slow the rate of renal function decline.
Authors: D Roth; R D Smith; G Schulman; T I Steinman; F E Hatch; M R Rudnick; J A Sloand; B I Freedman; W W Williams; C A Shadur Journal: Am J Kidney Dis Date: 1994-11 Impact factor: 8.860
Authors: Vivian Regina Tristão; Fernando Felippe de Carvalho; Cinthia Zanini Gomes; Adriana Regina Miranda; Cíntia C Vequi-Suplicy; Maria Teresa Lamy; Nestor Schor; Maria Helena Bellini Journal: J Fluoresc Date: 2010-02-23 Impact factor: 2.217